What is it about?
Intention is to foster the initial benefit of biologic agents in ulcerative colitis.
Featured Image
Photo by Fabio Ballasina on Unsplash
Why is it important?
Should we combine biologic agents and immunomodulators in ulcerative colitis ? And which one to consider or not to favor to increase the therapeutic efficacy of the first one ? Is it of benefit for each biologic agents ?
Perspectives
Specific patients, notably those who initially slowly or less response to biologic agents, not only when anti-biologics antibodies are expressed, immunomodulators may favor innate and adaptive immune benefits.
Philippe Pinton
Ferring Pharmaceuticals
Read the Original
This page is a summary of: Combination of vedolizumab and immunomodulators in ulcerative colitis, Journal of Gastroenterology and Hepatology, September 2021, Wiley,
DOI: 10.1111/jgh.15686.
You can read the full text:
Contributors
The following have contributed to this page
